NASDAQ : RNXT
RenovoRx, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.49 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 67.24M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 56.86M |
| Enterprise Value | 47.77M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 45.13M |
| Shares Outstanding | 45.13M |
| Shares Change (YoY) | +34.40% |
| Shares Change (QoQ) | +24.36% |
| Owned by Insiders (%) | 3.45% |
| Owned by Institutions (%) | 10.92% |
| Float | 39.17M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 28.78 |
| Forward PS | 8.93 |
| PB Ratio | 6.68 |
| P/TBV Ratio | 6.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 24.18 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.74 |
| Quick Ratio | 5.29 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -125.23% |
| Return on Assets (ROA) | -64.90% |
| Return on Invested Capital (ROIC) | -80.41% |
| Return on Capital Employed (ROCE) | -136.00% |
| Weighted Average Cost of Capital (WACC) | 9.54% |
| Revenue Per Employee | $116,235 |
| Profits Per Employee | -$722,647 |
| Employee Count | 17 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.97 |
| 52-Week Price Change | +12.61% |
| 50-Day Moving Average | 1.56 |
| 200-Day Moving Average | 1.10 |
| Relative Strength Index (RSI) | 42.76 |
| Average Volume (20 Days) | 400,163 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 864,570 |
| Short Previous Month | 946,982 |
| Short % of Shares Out | 1.92% |
| Short % of Float | 2.21% |
| Short Ratio (days to cover) | 1.47 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.98M |
| Gross Profit | 1.67M |
| Operating Income | -13.04M |
| Pretax Income | -12.29M |
| Net Income | -12.29M |
| EBITDA | -13.03M |
| EBIT | -13.04M |
| Loss Per Share | -$0.31 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 9.48M |
| Total Debt | 390,000 |
| Net Cash | 9.09M |
| Net Cash Per Share | $0.20 |
| Equity (Book Value) | 8.98M |
| Book Value Per Share | 0.20 |
| Working Capital | 8.93M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -11.87M |
| Capital Expenditures | -71,000 |
| Depreciation & Amortization | 6,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -11.94M |
| FCF Per Share | -$0.26 |
Margins
| Measure | Value |
|---|
| Gross Margin | 84.41% |
| Operating Margin | -659.92% |
| Pretax Margin | -621.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -34.40% |
| Shareholder Yield | -34.40% |
| Earnings Yield | -24.57% |
| FCF Yield | -20.99% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.13 |
| Price Target Difference | 465.48% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 210.23% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.43 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |